126 related articles for article (PubMed ID: 35987087)
1. Deep blue autofluorescence reflects the oxidation state of human transthyretin.
Wieczorek E; Wygralak Z; Kędracka-Krok S; Bezara P; Bystranowska D; Dobryszycki P; Ożyhar A
Redox Biol; 2022 Oct; 56():102434. PubMed ID: 35987087
[TBL] [Abstract][Full Text] [Related]
2. Deep blue autofluorescence reveals the instability of human transthyretin.
Wieczorek E; Bezara P; Ożyhar A
Int J Biol Macromol; 2021 Nov; 191():492-499. PubMed ID: 34562536
[TBL] [Abstract][Full Text] [Related]
3. Transthyretin: From Structural Stability to Osteoarticular and Cardiovascular Diseases.
Wieczorek E; Ożyhar A
Cells; 2021 Jul; 10(7):. PubMed ID: 34359938
[TBL] [Abstract][Full Text] [Related]
4. Age-related oxidative modifications of transthyretin modulate its amyloidogenicity.
Zhao L; Buxbaum JN; Reixach N
Biochemistry; 2013 Mar; 52(11):1913-26. PubMed ID: 23414091
[TBL] [Abstract][Full Text] [Related]
5. Destabilisation of the structure of transthyretin is driven by Ca
Wieczorek E; Kędracka-Krok S; Bystranowska D; Ptak M; Wiak K; Wygralak Z; Jankowska U; Ożyhar A
Int J Biol Macromol; 2021 Jan; 166():409-423. PubMed ID: 33129902
[TBL] [Abstract][Full Text] [Related]
6. Potentially amyloidogenic conformational intermediates populate the unfolding landscape of transthyretin: insights from molecular dynamics simulations.
Rodrigues JR; Simões CJ; Silva CG; Brito RM
Protein Sci; 2010 Feb; 19(2):202-19. PubMed ID: 19937650
[TBL] [Abstract][Full Text] [Related]
7. Transthyretin microheterogeneity and molecular interactions: implications for amyloid formation.
Landreh M; Ostberg LJ; Pettersson TM; Jörnvall H
Biomol Concepts; 2014 Jun; 5(3):257-64. PubMed ID: 25372757
[TBL] [Abstract][Full Text] [Related]
8. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease.
McCutchen SL; Lai Z; Miroy GJ; Kelly JW; Colón W
Biochemistry; 1995 Oct; 34(41):13527-36. PubMed ID: 7577941
[TBL] [Abstract][Full Text] [Related]
9. The importance of a gatekeeper residue on the aggregation of transthyretin: implications for transthyretin-related amyloidoses.
Sant'Anna R; Braga C; Varejão N; Pimenta KM; Graña-Montes R; Alves A; Cortines J; Cordeiro Y; Ventura S; Foguel D
J Biol Chem; 2014 Oct; 289(41):28324-37. PubMed ID: 25086037
[TBL] [Abstract][Full Text] [Related]
10. Cooperative stabilization of transthyretin by clusterin and diflunisal.
Greene MJ; Klimtchuk ES; Seldin DC; Berk JL; Connors LH
Biochemistry; 2015 Jan; 54(2):268-78. PubMed ID: 25478940
[TBL] [Abstract][Full Text] [Related]
11. S-sulfonation of transthyretin is an important trigger step in the formation of transthyretin-related amyloid fibril.
Nakanishi T; Yoshioka M; Moriuchi K; Yamamoto D; Tsuji M; Takubo T
Biochim Biophys Acta; 2010 Jul; 1804(7):1449-56. PubMed ID: 20388560
[TBL] [Abstract][Full Text] [Related]
12. Uncovering the Mechanism of Aggregation of Human Transthyretin.
Saelices L; Johnson LM; Liang WY; Sawaya MR; Cascio D; Ruchala P; Whitelegge J; Jiang L; Riek R; Eisenberg DS
J Biol Chem; 2015 Nov; 290(48):28932-43. PubMed ID: 26459562
[TBL] [Abstract][Full Text] [Related]
13. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.
Lai Z; Colón W; Kelly JW
Biochemistry; 1996 May; 35(20):6470-82. PubMed ID: 8639594
[TBL] [Abstract][Full Text] [Related]
14. Cys-10 mixed disulfide modifications exacerbate transthyretin familial variant amyloidogenicity: a likely explanation for variable clinical expression of amyloidosis and the lack of pathology in C10S/V30M transgenic mice?
Zhang Q; Kelly JW
Biochemistry; 2005 Jun; 44(25):9079-85. PubMed ID: 15966731
[TBL] [Abstract][Full Text] [Related]
15. Chromium(III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation.
Sato T; Ando Y; Susuki S; Mikami F; Ikemizu S; Nakamura M; Suhr O; Anraku M; Kai T; Suico MA; Shuto T; Mizuguchi M; Yamagata Y; Kai H
FEBS Lett; 2006 Jan; 580(2):491-6. PubMed ID: 16386248
[TBL] [Abstract][Full Text] [Related]
16. Transthyretin Misfolding, A Fatal Structural Pathogenesis Mechanism.
Si JB; Kim B; Kim JH
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922648
[TBL] [Abstract][Full Text] [Related]
17. Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis.
Mangione PP; Porcari R; Gillmore JD; Pucci P; Monti M; Porcari M; Giorgetti S; Marchese L; Raimondi S; Serpell LC; Chen W; Relini A; Marcoux J; Clatworthy IR; Taylor GW; Tennent GA; Robinson CV; Hawkins PN; Stoppini M; Wood SP; Pepys MB; Bellotti V
Proc Natl Acad Sci U S A; 2014 Jan; 111(4):1539-44. PubMed ID: 24474780
[TBL] [Abstract][Full Text] [Related]
18. Modulating conformational factors in transthyretin amyloid.
Saraiva MJ; Almeida MR; Alves IL; Bonifácio MJ; Damas AM; Palha JA; Goldsteins G; Lundgren E
Ciba Found Symp; 1996; 199():47-52; discussion 52-7. PubMed ID: 8915603
[TBL] [Abstract][Full Text] [Related]
19. Disease-associated mutations impacting BC-loop flexibility trigger long-range transthyretin tetramer destabilization and aggregation.
Esperante SA; Varejāo N; Pinheiro F; Sant'Anna R; Luque-Ortega JR; Alfonso C; Sora V; Papaleo E; Rivas G; Reverter D; Ventura S
J Biol Chem; 2021 Sep; 297(3):101039. PubMed ID: 34343569
[TBL] [Abstract][Full Text] [Related]
20. Plasma retinol-binding protein: structure and interactions with retinol, retinoids, and transthyretin.
Zanotti G; Berni R
Vitam Horm; 2004; 69():271-95. PubMed ID: 15196886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
